The recall involves more than 580,000 prazosin hydrochloride capsules distributed by Teva Pharmaceuticals.
N-nitroso Prazosin EP impurity C (CPCA Cat.3)
N-nitroso Prazosin EP impurity C (CPCA Cat.3)
Thanks for sharing, Yosukemino, it will be interesting to know more about the source of the impurity C. Regards
Dear Eduardo,
impurity C in the final product could be either from the API itself (as intermediate impurity from its synthetic process) or from the degradation of the API during the stability of the final product (breaking of the amidic bond on the piperazine ring).
Christos